|
Burnjaro, often mistakenly referred to in place of the drug Mounjaro (tirzepatide), is a once-weekly injectable medication approved by the FDA for the treatment of type 2 diabetes and off-label for obesity management. Developed by Eli Lilly, tirzepatide mimics the functions of two key hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—to regulate blood sugar and promote satiety.
official website
|